Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 2—February 2010

Research

Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies1

Anthony T. NewallComments to Author , James G. Wood, Noemie Oudin, and C. Raina MacIntyre
Author affiliations: University of New South Wales, Sydney, New South Wales, Australia (A.T. Newall, J.G. Wood, C.R. MacIntyre); National Institute for Applied Sciences, Lyon, France (N. Oudin)

Main Article

Figure 2

Sensitivity analyses of clinical outcomes as key parameters are varied. In A–C, the clinical attack rate (CAR) is displayed as a function of R0 and vaccine efficacy (VE) (A), vaccine coverage and VE (B), and the delay to vaccination (C). In D, deaths prevented per 100,000 population compared with no intervention is displayed as a function of R0.

Figure 2. Sensitivity analyses of clinical outcomes as key parameters are varied. In A–C, the clinical attack rate (CAR) is displayed as a function of R0 and vaccine efficacy (VE) (A), vaccine coverage and VE (B), and the delay to vaccination (C). In D, deaths prevented per 100,000 population compared with no intervention is displayed as a function of R0.

Main Article

1This material was compiled before the declaration of pandemic (H1N1) 2009 and concerns stockpiling for a future influenza pandemic.

TOP